| scholarly article | Q13442814 |
| P2093 | author name string | Lori McLeod | |
| Marina Magrey | |||
| Margaret Mordin | |||
| Costel Chirila | |||
| Peter Hur | |||
| Eric Davenport | |||
| Daniel Wolin | |||
| Michael Bozyczko | |||
| P2860 | cites work | Patient satisfaction as an indicator of quality care | Q39485640 |
| Performance of screening tools for psoriatic arthritis: a cross-sectional study in primary care | Q40408596 | ||
| The use of patient perceptions in the evaluation of health-care delivery systems | Q41641201 | ||
| Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011. | Q46272550 | ||
| Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial | Q46585904 | ||
| Early treatment of psoriatic arthritis is associated with improved patient-reported outcomes: findings from the etanercept PRESTA trial. | Q48055281 | ||
| Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study. | Q52650418 | ||
| Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. | Q53125208 | ||
| Epidemiology of psoriatic arthritis in the population of the United States. | Q53276933 | ||
| Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data | Q64069627 | ||
| Involvement, satisfaction and unmet health care needs in patients with psoriatic arthritis | Q79771586 | ||
| Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial | Q81300604 | ||
| Ustekinumab in psoriatic arthritis: need for studies from real-world evidence | Q90466438 | ||
| A Pilot Study to Assess the Feasibility of a Web-Based Survey to Examine Patient-Reported Symptoms and Satisfaction in Patients with Ankylosing Spondylitis Receiving Secukinumab | Q91754409 | ||
| International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials | Q30841346 | ||
| Discordance of Global Assessments by Patient and Physician Is Higher in Female than in Male Patients Regardless of the Physician's Sex: Data on Patients with Rheumatoid Arthritis, Axial Spondyloarthritis, and Psoriatic Arthritis from the DANBIO Regi | Q30984432 | ||
| Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report. | Q31130672 | ||
| Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial | Q35555905 | ||
| Psoriatic arthritis: epidemiology, clinical features, course, and outcome | Q35579437 | ||
| US Perspectives in the Management of Psoriasis and Psoriatic Arthritis: Patient and Physician Results from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey | Q36521222 | ||
| RAPID3, an index to assess and monitor patients with rheumatoid arthritis, without formal joint counts: similar results to DAS28 and CDAI in clinical trials and clinical care | Q37644857 | ||
| Psoriatic arthritis: current therapy and future approaches | Q38240116 | ||
| Clinical Features and Diagnostic Considerations in Psoriatic Arthritis | Q38609814 | ||
| Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis | Q38691418 | ||
| Incorporating the patient's perspective in outcomes research | Q38772280 | ||
| Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: results from a randomised phase III trial (FUTURE 1). | Q38868356 | ||
| Misalignment between physicians and patient satisfaction with psoriatic arthritis disease control | Q38941723 | ||
| Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis | Q38958215 | ||
| Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial | Q38989105 | ||
| P433 | issue | 12 | |
| P921 | main subject | psoriatic arthritis | Q511097 |
| P304 | page(s) | 1205-1212 | |
| P577 | publication date | 2019-12-01 | |
| P1433 | published in | Clinical Drug Investigation | Q15753215 |
| P1476 | title | Evaluation of the Feasibility of a Web-Based Survey to Assess Patient-Reported Symptom Improvement and Treatment Satisfaction Among Patients with Psoriatic Arthritis Receiving Secukinumab | |
| P478 | volume | 39 |
Search more.